Currently, there is an unmet need for the development of rapid-acting antidepressants aimed at treatment-resistant patients with either major depressive disorder (MDD) or bipolar disorder. A review of existing treatment options, as well as future possibilities, was published in Psychiatry and Clinical Neurosciences.